fda approved weight loss glp-1 The New Management Meds FDA Approves First ORAL GLP-1

AOD 9604: Derived from human growth hormone, it specifically targets fat metabolism without affecting blood sugar or growth

NICE guideline NG222 for depression in adults does not include GLP-1 receptor agonists among recommended treatments

Preclinical and clinical data, though predominantly derived from case reports and small cohort studies to date, consistently indicate that GLP-1 RAs - including liraglutide, semaglutide, and the dual GIP/GLP-1 RA tirzepatide - can induce clinically meaningful weight loss, suppress the characteristic severe hyperphagia, and improve key cardiometabolic parameters in both heterozygous and homozygous MC4R variant carriers

FDA seized the identified counterfeit products on April 9, 2025

Additionally, those who have experienced severe allergic reactions to tirzepatide or its ingredients should refrain from using it

In summary, GLP-1 and GLP-1R show expression in a variety of tissues and the best-studied and most currently clinically relevant effects of GLP-1 is its ability to act as an incretin hormone and reduce appetite, given the global prevalence of T2D and obesity